NET Clinical Trials in Canada

The following information on active neuroendocrine clinical trials in Canada was taken from the clinicaltrials.gov website. Click on each trial to go to more information including protocol, objectives, entry criteria, investigators and locations in Canada.

For an up-to-date listing of all active recruiting trials please visit: Neuroendocrine Tumour Open Trials – Canada

Neuroendocrine Tumour Canada | Open StudiesR3R2

 Status / Clinical Trial
1 Recruiting Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors

Conditions: Neuroendocrine Tumors;   Pancreatic Neuroendocrine Tumors
Intervention:
2 Recruiting A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours

Condition: Carcinoma, Neuroendocrine
Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
3 Not yet recruiting Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Condition: Neuroendocrine Tumors
Intervention: Drug: Lutetium-177 Octreotate
4 Recruiting Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors

Condition: Neuroendocrine Tumors
Interventions: Drug: Lanreotide (Autogel formulation);   Drug: Placebo
5 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Condition: Advanced Cancer
Intervention: Biological: pembrolizumab
6 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

Conditions: Cushing’s Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
7 Recruiting Personalized PRRT of Neuroendocrine Tumors

Conditions: Neuroendocrine Tumors;   Carcinoid Tumor;   Carcinoma, Neuroendocrine
Intervention: Drug: 177Lu-Octreotate
8 Available 18F-FDOPA PET in Neuroendocrine Tumours

Conditions: Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
Intervention: Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
9 Unknown † Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours

Conditions: Renal Cell Carcinoma;   Neuroendocrine Tumours
Intervention: Drug: 18F-FAZA PET Imaging
10 Unknown † 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Conditions: Pheochromocytoma;   Neuroblastoma;   Paraganglioma;   Medullary Thyroid Carcinoma;   Carcinoid Tumors
Intervention: Drug: 123I-meta-iodobenzylguanidine
11 Recruiting Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors

Condition: Neuroendocrine Tumors
Intervention: Other: Gallium-68 DOTA TATE PET scan
12 Not yet recruiting An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis

Condition: Carcinoma, Neuroendocrine
Intervention: Drug: Everolimus